OraVescent® drug delivery system: A novel technology for the transmucosal delivery of drugs

Modified-Release Drug Delivery Technology, Second Edition

Volumn 1, Issue , 2008, Pages 83-92

  Hamed, Ehab ^a   Durfee, Steve L ^b  

^a CIMA Labs Inc Minnesota   (United States)

^b Cephalon Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77952850880     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (30)

1. Cooper. Improvements in preparing or making up medicated and other effervescing mixtures. British patent 3160.
2. Eichman JD, Robinson JR. Mechanistic studies on effervescent-induced permeability enhancement. Pharm Res 1998; 15: 925-30.
3. Shore PA, Brodie BB, Hogben CA. The gastric secretion of drugs: a pH partition hypothesis. J Pharmacol Exp Ther 1957; 119: 361-9.
4. Leveque N, Makki S, Hadgraft J, Humbert P. Comparison of Franz cells and microdialysis for assessing salicylic acid penetration through human skin. Int J Pharm 2004; 269: 323-8.
5. Smith JC, Irwin WJ. Ionisation and the effect of absorption enhancers on transport of salicylic acid through silastic rubber and human skin. Int J Pharm 2000; 210: 69-82.
6. Francoeur ML, Golden GM, Potts RO. Oleic acid: Its effects on stratum corneum in relation to (trans)dermal drug delivery. Pharm Res 1990; 7: 621-7.
7. Hadgraft J, Valenta C. pH, pK(a) and dermal delivery. Int J Pharm 2000; 200: 243-7.
8. Rathbone MJ, Tucker IG. Mechanisms, barriers and pathways of oral mucosal drug permeation. Adv Drug Delivery Rev 1993; 12: 41-60.
9. Nicolazzo JA, Reed BL, Finnin BC. Buccal penetration enhancers-how do they really work? J Control Release 2005; 105:1-15.
10. Birudaraj R, Berner B, Shen S, Li X. Buccal permeation of buspirone: mechanistic studies on transport pathways. J Pharm Sci 2005; 94: 70-8.
11. McElnay JC, Al-Furaih TA, Hughes CM, Scott MG, Elborn JS, Nicholls DP. Buccal absorption of enalapril and lisinopril. Eur J Clin Pharmacol 1998; 54: 609-14.
12. Pather SI, Khankari R, Siebert J. OraVescent: A Novel Technology for the Transmucosal Delivery of Drugs. In: Modified-Release Drug Delivery Technology. Rathbone MJ, Hadgraft J, Roberts MS, eds. New York: Marcel Dekker, 2003: pp. 463-216.
13. ACD/Labs, Version 10.0. Advanced Chemistry Development, Inc. Toronto, Ontario, Canada.
14. ACD/LogD, Version 10.0. Advanced Chemistry Development, Inc. Toronto, Ontario, Canada.
15. ACD/Solubility DB, Version 10.0. Advanced Chemistry Development, Inc. Toronto, Ontario, Canada.
16. Darwish M, Kirby M, Robertson P, Tracewell W, Jiang JG. Absolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrate. J Clin Pharmacol 2007; 47(3): 343-50.
17. Darwish M, Kirby M, Robertson P, Tracewell W, Jiang JG. Comparative bioavailability of the novel fentanyl effervescent buccal tablet formulation: an open-label crossover study. Poster Presentation at the American Pain Society Annual Meeting, May 3-6, San Antonio, TX, 2006.
18. Darwish M, Kirby M, Robertson P, Hellriegel E, Jiang JG. Single-dose and steady-state pharmacokinetics of fentanyl buccal tablet in healthy volunteers. J Clin Pharmacol 2007; 47(1): 56-63.
19. Darwish M, Tempro K, Kirby M, Thompson J. Pharmacokinetics and dose proportionality of fentanyl effervescent Buccal tablets in healthy volunteers. Clin Pharmacokinet 2005; 44(12): 1279-86.
20. Darwish M, Kirby M, Robertson P, Tracewell W, Jiang JG. Pharmacokinetic properties of fentanyl effervescent buccal tablets: an open-label, crossover study in healthy adults. Poster Presentation at the American Academy of Pain Medicine Annual Meeting, February 22-25, San Diego, CA, 2006.
21. Darwish M, Kirby M, Robertson P, Tracewell W, Jiang JG. Pharmacokinetic properties of fentanyl effervescent buccal tablets: a phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 microg in healthy adult volunteers. Clin Ther 2006; 28(5): 707-14.
22. Darwish M, Messina J, Tempro K. Relative bioavailability and dose proportionality of a novel effervescent form of fentanyl in healthy volunteers. Poster Presentation at the American Society of Anesthesiologists Annual Meeting, October 24, Atlanta, GA, 2005.
23. Portenoy R, Taylor D, Messina J, Tremmel L. Fentanyl effervescent buccal tablets for relief of breakthrough pain in opioid-treated patients with cancer: a randomized, placebo-controlled study. Poster Presentation at the American Pain Society Annual Meeting, May 3-6, San Antonio, TX, 2006.
24. Webster L, Taylor D, Peppin J, Niebler G. Open-label study of fentanyl effervescent buccal tablets in patients with chronic noncancer pain and breakthrough pain: patient preference assessment. Poster Presentation at the American Pain Society Annual Meeting, May 3-6, San Antonio, TX, 2006.
25. Portenoy RK, Bennett DS, Rauck R, Simon S, Taylor D, Brennan M, Shoemaker S. Prevalence and characteristics of breakthrough pain in opioid-treated patients with chronic noncancer pain. J Pain 2006; 7(8): 583-91.
26. Portenoy R, Taylor D, Messina J, Tremmel L. A randomized, placebocontrolled study of fentanyl buccal tablet for breakthrough pain in opioidtreated patients with cancer. Clin J Pain 2006; 22(9): 805-11.
27. Blick SK, Wagstaff AJ. Fentanyl buccal tablet: in breakthrough pain in opioidtolerant patients with cancer. Drugs 2006; 66(18): 2387-93; discussion 2394-5.
28. Segal T, Jhangiani H, Niebler G. Patients experience with fentanyl effervescent buccal tablets: interim analysis of a long-term, multicenter, open label study in cancer-related breakthrough pain. Poster Presentation at the American Pain Society Annual Meeting, May 3-6, San Antonio, TX, 2006.
29. Hale M, Webster L, Peppin J, Messina J. Open-label study with fentanyl effervescent buccal tablets in patients with chronic pain and breakthrough pain:interim safety and tolerability results. Poster Presentation at the American Academy of Pain Medicine Annual Meeting, February 22-25, San Diego, CA, 2006.
30. Portenoy RK, Messina J, Xie F, Peppin J. Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study. Curr Med Res Opin 2007; 23(1): 223-33.